KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
KEYTRUDA
Date registered
Evaluation commenced
Decision date
Approval time
163 (255 working days)
Active ingredients
pembrolizumab
Registration type
EOI
Indication
Ovarian Cancer
TRADE NAME (pembrolizumab), in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinumresistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumours express PD-L1 (CPS≥1) as determined by a validated test, and who have received one or two prior systemic treatment regimens.